Navigation Links
Neurotransmitters resarch can promote better drugs for brain disorders
Date:1/7/2014

Jerusalem, January 7, 2014 -- Although drugs have been developed that inhibit the imbalance of neurotransmitters in the brain a condition which causes many brain disorders and nervous system diseases the exact understanding of the mechanism by which these drugs work has not yet been fully explained.

Now, researchers at the Hebrew University of Jerusalem, using baker's yeast as a model, have deciphered the mode by which the inhibitors affect the neurological transmission process and have even been able to manipulate it.

Their work, reported in a recent article in the Journal of Biological Chemistry, raises hopes that these insights could eventually guide clinical scientists to develop new and more effective drugs for brain disorders associated with neurotransmitter imbalance.

All of the basic tasks of our existence are executed by the brain whether it is breathing, heartbeat, memory building or physical movements which depend on the highly regulated and efficient release of neurotransmitters chemicals that act as messengers enabling extremely rapid connections between the neurons in the brain.

When even one part of the everyday "conversation" between neighboring neurons breaks down, the results can be devastating. Many brain disorders and nervous system diseases, including Huntington's disease, various motor dysfunctions and even Parkinson's disease, have been linked to problems with neurotransmitter transport.

The neurotransmitters are stored in the neuron in small, bubble-like compartments, called vesicles, containing transport proteins that are responsible for the storage of the neurotransmitters into the vesicles.

The storage of certain neurotransmitters is controlled by what is called the vesicular monoamine transporter (VMAT), which is known to transport a variety of vital neurotransmitters, such as adrenaline, dopamine and serotonin.

In addition, it can also transport the detrimental MPP+, a neurotoxin involved in models of Parkinson's disease.

A number of studies demonstrated the significance of VMAT as a target for drug therapy in a variety of pathologic states, such as high blood pressure, hyperkinetic movement disorders and Tourette syndrome.

Many of the drugs that target VMAT act as inhibitors, including the classical VMAT2 inhibitor, tetrabenazine. Tetrabenazine has long been used for the treatment of motor dysfunctions associated with Huntington's disease and other movement disorders. However, the mechanism by which the drug affects the storage of neurotransmitters was not fully understood.

The Hebrew University study set out, therefore, to achieve an understanding of the basic biochemical mechanism underlying the VMAT reaction, with a view towards better controlling it through new drug designs.

The research was conducted by in the laboratory of Prof. Shimon Schuldiner of the Hebrew University's Department of Biological Chemistry; Dr.Yelena Ugolev, postdoctoral fellow in the laboratory; and research students Tali Segal, Dana Yaffe and Yael Gros.

To identify protein sequences responsible for tetrabenazine binding, the Hebrew University scientists harnessed the power of yeast genetics along with the method of directed evolution.

Expressing the human protein VMAT in baker's yeast cells confers them with the ability to grow in the presence of toxic substrates, such as neurotoxin MPP+. Directed evolution mimics natural evolution in the laboratory and is a method used in protein engineering.

By using rounds of random mutations targeted to the gene encoding the protein of interest, the proteins can be tuned to acquire new properties or to adapt to new functions or environment.

The study led to identification of important flexible domains (or regions) in the structure of the VMAT, responsible for producing optional rearrangements in tetrabenazine binding, and also enabling regulation of the velocity of the neurotransmitter transporter.

Utilizing these new, controllable adaptations could serve as a guide for clinical scientists to develop more efficient drugs for brain disorders associated with neurotransmitter imbalance, say the Hebrew University researchers.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Related biology news :

1. Research shows how PCBs promote dendrite growth, may increase autism risk
2. Interacting mutations promote diversity
3. Single protein promotes resistance to widely used anti-estrogen drugs
4. An economical, effective and biocompatible gene therapy strategy promotes cardiac repair
5. New Genetics educational resource promotes active learning
6. Breast milk promotes a different gut flora growth than infant formulas
7. Antibiotic residues in sausage meat may promote pathogen survival
8. Desert farming forms bacterial communities that promote drought resistance
9. NJIT professor promotes building material of millennium: Autoclave aerated concrete
10. Team finds gene that promotes drug resistance in cancer
11. Dr. Anne Lindblad Promoted To President/CEO Of The EMMES Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Neurotransmitters resarch can promote better drugs for brain disorders
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... FireflySci cuvettes are used in leading laboratories all over the globe. Their ... , In addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... by the Office of the National Coordinator for Health IT (ONC) outlining a ... clinically relevant data were available when and where it was needed. The organization ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell ... injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded ... healing and tissue regeneration. , The novel method, developed by WPI faculty members ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... Will Drive Precision Farming in 2017 and Beyond. The paper outlines the key ... the precision ag industry. , “We’ve witnessed a lot of highs and lows ...
Breaking Biology Technology: